Keywords
How to Cite
Abstract
In a retrospective study during the primary mode MOPP to primary patients LH II/ IVAB stages with a poor prognosis rate of CR., 5—and 10-year DFS, OS was 69%, 71% and 68%, 74% and 64%, ABVD—76%, 78%, 83% and 68%, BEACOPP-baseline—73%, 97%, 85% and 82% correspondingly. When the program ran ВЕАСОРР-baseline it was revealed higher rates of DFS compared with ABVD and MOPP. Higher OS rates were observed in the primary patients treated with BEACOPP-baseline compared with MOPP (p = 0.04). In terms of DFS and OS MOPP regimen did not differ from ABVD. Program ABVD and ВЕАСОРР-baseline had no differences in terms of OS. The frequency of primary refractory forms of LH did not depend on the conducted regimens of PCT. Significantly less the recurrences occurred during the regimen of BEACOPP-baseline compared to MOPP and ABVD. BEACOPP-baseline was accompanied by a more pronounced reversible hematologic toxicity. Against the background of the program BEACOPP-baseline, neutropenia of III-IV degree was detected in 32%, ABVD—16%, MOPP— 13%.References
Демина Е.А. Современные критерии оценки эффективности терапии больных злокачественными лимфомами // Вместе против рака. Врачам всех специальностей. — 2006. — № 2. — С. 13-16.
Bartlett N.L., Niedzwiecki D., Johnson L. et al. Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin’s lymphoma: CALGB 59804 // Ann. Oncol. — 2007. — Vol. 18. — P. 1071-1079.
Brice P. Managing relapsed and refractory Hodgkin lymphoma // Brit J. Haematol. - 2008. — Vol. 141. — P. 3-13.
Canellos G.P., Anderson J.R., Propert J.R. et al. Chemotherapy of advanced Hodgkin’s disease with MOPP, ABVD or MOPP alternating with ABVD // N. Engl. J. Med. — 1992. — Vol. 327. — P. 1478-1484.
Canellos G.P., Gollub J., Neuberg D. et al. Primary systemic treatment of advanced Hodgkin’s disease with EVA (etoposide, vinblastine, doxorubicin): 10-year follow-up // Ann. Oncol. — 2003. — Vol. 14. — P. 268-272.
Carbone P.P., Kaplan H.S., Musshoff K. et al. Report of the Committee on Hodgkin’s Disease Staging Classification // Cancer Res. -1971. — Vol. 31. — P. 1860-1861.
Connors J.M., Klimo P., Adams G. et al. Treatment of advanced Hodgkin’s disease with chemotherapy: comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD., a report from the NCi of Canada clinical trials group // J. Clin. Oncol. — 1997. — Vol. 17. — P. 1638-1645.
De Vita V.T., Serpick A.A., Carbone P.P. Combination chemotherapy in the treatment of advanced Hodgkin‘s disease // Ann. Intern. Med. — 1970. — Vol. 73. — P. 881 -895.
Diehl V., Franklin J., Pfreundschuh M. et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin‘s disease // N. Engl. J. Med. — 2003. — Vol. 348. — P. 2386-2395.
Duggan D.B., Petroni F.R., Johnson J.L. et al. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin‘s disease: report of an intergroup trial // J. Clin. Oncol. — 2003. — Vol. 21. — P. 607-614.
Engert A., Diehl V., Franclin J. et al. Escaleted-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin‘s lymphoma: 10 years of follow-up of the GHSG HD9 study // J. Clin. Oncol. — 2009. — Vol. 27. — P. 4548-4554.
Franklin J., Diehl V. Dose escalated BEACOPP chemotherapy regimen for advanced stage Hodgkin‘s disease: final analysis of the HD9 randomized trial of the GHSG // Ann. Oncol. — 2002. — Vol. 13 (suppl. 1). — P. 98-101.
Gallamini A., Rigacci L., Merli F. et al. The predictive value of positron emission tomography scanning performed after two courses of standart therapy on treatment outcome in advanced stage Hodgkin’s disease // Haematologia — 2006. -Vol. 91. — P. 475-481.
Gobbi P.G., Pieresca C., Federico M. et al. MOPP/EBV/CAD hybrid chemotherapy with or without limited radiotherapy in advanced or unfavorably presenting Hodgkin’s disease: A report from the jtalian Lymphoma Study Group // J. Clin. Oncol. — 1993. — Vol. 11. — P. 712-719.
Gobbi P.G., Pieresca C., Ghirardelli M.L. et al. Long-term results from MOPPEBVCAD chemotherapy with optional limited radiotherapy in advanced Hodgkin’s disease // Blood-1998. — Vol. 91. — P. 2704-2712.
Horning S.J. Primary refractory Hodgkin’s disease // Ann. Oncol. — 1998. — Vol. 9 (suppl. 5). — P. 97-101.
Horning S.J., Hoppe R.T., Breslin S. et al. Stanford V and radiotherapy for locally extensive and advanced Hodgkin’s disease: Mature results of a prospective clinical trial // J. Clin. Oncol. — 2002. — Vol. 20. — P. 630-637.
Martinelli G., Cocorocchio E., Peccatori F. et al. ChlVPP/ABVVP a firstline hybrid combination chemotherapy for advanced Hodgkin’s lymphoma: A retrospective analysis // Brit. J. Haematol. — 2004. — Vol. 125. — P. 584-589.
Sieber M., Tesch H., Pfistner B. et al. Treatment of advanced Hodgkin’s disease with COPP/ABV/MEP versus COPP/ABVD and consolidating radiotherapy: Final results of the German Hodgkin’s Lymphoma Study Group HD6 trial // Ann. Oncol. — 2004. — Vol. 15. — P. 276-282.
Trotti A., Colevas A.D., Setser A., Rusch V., Joques D., Budach V., Langer C., Murphy B., Cumberlin R., Coleman C.N., Rubin P. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment // Semin. Radiat. Oncol. — 2003. — Vol. 13. — P. 176-181.
Viviani S., Bonadonna G., Santoro A. et al. Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin’s disease: ten-year results // J. Clin. Oncol. — 1996. — Vol. 14. — P. 603-609.
Viviani S., Bonfante V., Santoro A. et al. Long-term results of an intensive regimen: VEBEP plus involved-field radiotherapy in advanced Hodgkin’s disease // Cancer. — 1999. — Vol. 5. — P. 275-282.
Viviani S., Zinzani P.L., Rambaldi A. et al. ABVD versus BEACOPP for Hodgkin’s lymphoma when high-dose salvage is planned // N. Engl. J. Med. — 2011. — Vol. 365. — P. 203-212.
Wedgwood A.R., Fanale M.A., Fayad L.E. et al. Rituximab + ABVD improves event free survival in patients with classical Hodgkin lymphoma who have PET positive disease after 2-3 cycles of therapy // Haematologica. — 2007. -Vol. 92 (suppl. 5). — P. 75 (Abstr. P129).
All the Copyright statements for authors are present in the standart Publishing Agreement (Public Offer) to Publish an Article in an Academic Periodical 'Problems in oncology' ...